<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>2236</number>
    <updateDate>2020-02-10T17:00:02Z</updateDate>
    <updateDateIncludingText>2020-02-10T17:00:02Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <originChamberCode>S</originChamberCode>
    <type>S</type>
    <introducedDate>2012-03-26</introducedDate>
    <congress>112</congress>
    <committees>
      <item>
        <systemCode>sshr00</systemCode>
        <name>Health, Education, Labor, and Pensions Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2012-03-26T22:30:37Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.</title>
        <congress>112</congress>
        <number>5334</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2012-05-11</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Food and Drug Administration Safety and Innovation Act</title>
        <congress>112</congress>
        <number>2516</number>
        <type>S</type>
        <latestAction>
          <actionDate>2012-05-07</actionDate>
          <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 389.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Food and Drug Administration Safety and Innovation Act</title>
        <congress>112</congress>
        <number>3187</number>
        <type>S</type>
        <latestAction>
          <actionDate>2012-07-09</actionDate>
          <text>Became Public Law No: 112-144.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2012-03-26</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2012-03-26</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>B001267</bioguideId>
        <fullName>Sen. Bennet, Michael F. [D-CO]</fullName>
        <firstName>Michael</firstName>
        <lastName>Bennet</lastName>
        <party>D</party>
        <state>CO</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>H000338</bioguideId>
        <fullName>Sen. Hatch, Orrin G. [R-UT]</fullName>
        <firstName>ORRIN</firstName>
        <lastName>HATCH</lastName>
        <party>R</party>
        <state>UT</state>
        <middleName>GRANT</middleName>
        <sponsorshipDate>2012-03-26</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>B001135</bioguideId>
        <fullName>Sen. Burr, Richard [R-NC]</fullName>
        <firstName>Richard</firstName>
        <lastName>Burr</lastName>
        <party>R</party>
        <state>NC</state>
        <middleName>Mauze</middleName>
        <sponsorshipDate>2012-03-26</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <notes>
      <item>
        <text><![CDATA[For further action, see S.3187, which became Public Law 112-144 on 7/9/2012.]]></text>
      </item>
    </notes>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative law and regulatory procedures</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Drug therapy</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2012-03-26</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2012-05-14T17:02:48Z</updateDate>
        <text><![CDATA[ <p>Advancing Breakthrough Therapies for Patients Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services (HHS), at the request of the sponsor of a drug, to expedite the drug's development and review if: (1) it is intended, either alone or in combination, to treat a serious life-threatening disease or condition; and (2) preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.</p> <p>Authorizes the drug's sponsor to request the Secretary to designate the drug as a breakthrough therapy. Requires the Secretary, within 60 days of such request, to determine whether the drug meets such criteria and, if so, make such designation, followed by appropriate actions to expedite its development and review for approval.</p> <p>Directs the Secretary to issue guidance on implementing requirements with respect to breakthrough therapies and to amend promulgated regulations.</p> <p>Requires the Secretary to contract with an independent entity to evaluate the manner by which the Food and Drug Administration (FDA) has applied the processes for the breakthrough therapy determination, and the impact of such processes on the development and timely availability of innovative treatments for patients affected by serious or life-threatening conditions. Requires an annual report from the Secretary to Congress on drugs for which breakthrough designations were requested and approved.</p>]]></text>
      </summary>
    </summaries>
    <title>Advancing Breakthrough Therapies for Patients Act of 2012</title>
    <titles>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Advancing Breakthrough Therapies for Patients Act of 2012</title>
      </item>
      <item>
        <titleType>Display Title</titleType>
        <title>Advancing Breakthrough Therapies for Patients Act of 2012</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to provide for the expedited development and evaluation of drugs designated as breakthrough drugs.</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2012-03-26T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-112s2236is/xml/BILLS-112s2236is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2012-03-26</actionDate>
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
